Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression. In addition, the company develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas. Show more
Location: 2617 Bissonnet Street, Houston, TX, 77005, United States | Website: https://www.alaunos.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
8.411M
52 Wk Range
$1.31 - $7.00
Previous Close
$5.13
Open
$5.04
Volume
56,249
Day Range
$4.68 - $5.09
Enterprise Value
8.092M
Cash
319K
Avg Qtr Burn
-956.5K
Insider Ownership
9.18%
Institutional Own.
3.59%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
TCR-T targeting neoantigens Details Cancer, Solid tumor/s | Failed Discontinued |